Literature DB >> 23428224

M1 and M2 Macrophages: Oracles of Health and Disease.

Charles D Mills1.   

Abstract

The purpose of immunology is simple. Cure or prevent disease. M1/M2 is useful because it is simple. M1/M2 describes the two major and opposing activities of macrophages. M1 activity inhibits cell proliferation and causes tissue damage while M2 activity promotes cell proliferation and tissue repair. Remarkably, the molecules primarily responsible for these "Fight" (NO) or "Fix" (Ornithine) activities both arise from arginine, and via enzymatic pathways (iNOS and arginase) that down regulate each other. The names M1 and M2 were chosen because M1 and M2 macrophages promote Th1 and Th2 responses, respectively. Products of Th1 and Th2 responses (e.g., IFN-γ, IL-4) also down regulate M2 and M1activity, respectively. Thus, M1/M2 demonstrated the importance of Innate Immunity and how it is linked to Adaptive Immunity in a beautifully counterbalanced system. "Civilization" and increased longevity present new disease challenges such as cancer and atherosclerosis that do not display classical "foreign" antigens. And, these diseases are often associated with (or caused by) M1- or M2- type responses that were formerly useful for fighting infections, but now are inappropriate in our increasingly "germ-free" societies. In turn, there is considerable potential for modulating M1 or M2 Innate responses in modern diseases to achieve better health. Finally, since M1 and Th1 (or M2 and Th2) often work in concert to produce characteristic immune responses and disease pathologies, it is recommended that Immune Type 1 or 2 (IT1, IT2) would be a simpler and unifying terminology going forward.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23428224     DOI: 10.1615/critrevimmunol.v32.i6.10

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  370 in total

Review 1.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

2.  Differences in forward angular light scattering distributions between M1 and M2 macrophages.

Authors:  David L Halaney; Aydin Zahedivash; Jennifer E Phipps; Tianyi Wang; Jordan Dwelle; Claude Jourdan Le Saux; Reto Asmis; Thomas E Milner; Marc D Feldman
Journal:  J Biomed Opt       Date:  2015-11       Impact factor: 3.170

Review 3.  Immunological memory: lessons from the past and a look to the future.

Authors:  Donna L Farber; Mihai G Netea; Andreas Radbruch; Klaus Rajewsky; Rolf M Zinkernagel
Journal:  Nat Rev Immunol       Date:  2016-02       Impact factor: 53.106

Review 4.  Sequential Immune Responses: The Weapons of Immunity.

Authors:  Charles D Mills; Klaus Ley; Kurt Buchmann; Johnathan Canton
Journal:  J Innate Immun       Date:  2015-04-02       Impact factor: 7.349

5.  Regulation of inflammation and fibrosis by macrophages in lymphedema.

Authors:  Swapna Ghanta; Daniel A Cuzzone; Jeremy S Torrisi; Nicholas J Albano; Walter J Joseph; Ira L Savetsky; Jason C Gardenier; David Chang; Jamie C Zampell; Babak J Mehrara
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

6.  Tumor cells express pauci- and oligomannosidic N-glycans in glycoproteins recognized by the mannose receptor (CD206).

Authors:  Kathrin Stavenhagen; Lisa C Laan; Chao Gao; Akul Y Mehta; Jamie Heimburg-Molinaro; Jonathan N Glickman; Irma van Die; Richard D Cummings
Journal:  Cell Mol Life Sci       Date:  2021-06-05       Impact factor: 9.261

7.  TIPS pentacene loaded PEO-PDLLA core-shell nanoparticles have similar cellular uptake dynamics in M1 and M2 macrophages and in corresponding in vivo microenvironments.

Authors:  Dylan K McDaniel; Ami Jo; Veronica M Ringel-Scaia; Sheryl Coutermarsh-Ott; Daniel E Rothschild; Michael D Powell; Rui Zhang; Timothy E Long; Kenneth J Oestreich; Judy S Riffle; Richey M Davis; Irving C Allen
Journal:  Nanomedicine       Date:  2016-12-29       Impact factor: 5.307

8.  Graft-Infiltrating Macrophages Adopt an M2 Phenotype and Are Inhibited by Purinergic Receptor P2X7 Antagonist in Chronic Rejection.

Authors:  C Wu; Y Zhao; X Xiao; Y Fan; M Kloc; W Liu; R M Ghobrial; P Lan; X He; X C Li
Journal:  Am J Transplant       Date:  2016-05-02       Impact factor: 8.086

9.  Cell based metabolic barriers to glucose diffusion: macrophages and continuous glucose monitoring.

Authors:  Ulrike Klueh; Jackman T Frailey; Yi Qiao; Omar Antar; Donald L Kreutzer
Journal:  Biomaterials       Date:  2014-01-22       Impact factor: 12.479

Review 10.  Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration.

Authors:  Joseph E Qualls; Peter J Murray
Journal:  Semin Immunopathol       Date:  2015-10-21       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.